Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00083694 · ClinicalTrials.gov registry record · Phase 2
Thalidomide Anti-Angiogenesis Therapy of Relapsed or Refractory Leukemia
A Phase 2 study, sponsored by University of Arkansas.
- Completed
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
NCT00083694 is a Phase 2 study that has completed, run by University of Arkansas. The registered enrollment target is 25 participants.
The verdict
NCT00083694, a Phase 2 study, has completed, sponsored by University of Arkansas.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and safety of Thalidomide in patients with leukemia.
Interventions
- DRUG Thalidomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 1998-08 |
| Est. Completion | 2005-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00083694
The ClinicalTrials.gov registry entry for NCT00083694 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Arkansas, which has 318 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Thalidomide is the first listed.
NCT00083694 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00083694 about?
NCT00083694 is a clinical study titled "Thalidomide Anti-Angiogenesis Therapy of Relapsed or Refractory Leukemia". The purpose of this study is to evaluate the efficacy and safety of Thalidomide in patients with leukemia.
What is the current status of trial NCT00083694?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 1998-08. Estimated completion is 2005-05.
What interventions are being tested in trial NCT00083694?
The interventions under investigation include: Thalidomide (DRUG).
Who is sponsoring clinical trial NCT00083694?
This trial is sponsored by University of Arkansas, which has 318 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.